Stocks News

LAST PRICE
47.7100
TODAY'S CHANGE (%)
Trending Up0.2000 (0.4210%)

Bid / Lots
47.7200/ 1
Ask / Lots
48.0000/ 4
Open / Previous Close
47.5200 / 47.5100
Day Range
Low 47.1600
High 48.1900
52 Week Range
Low 19.8301
High 94.7500
Volume
15,504
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Apr 17, 2024
- DJ Apellis Pharmaceuticals Is Maintained at Neutral by Wedbush, from 12:37PM ET on Wednesday Apr 17, 2024 by Dow Jones
  12:37PM ET on Wednesday Apr 17, 2024 by Dow Jones
  Companies Mentioned: APLS
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/APLS/analyst-ratings
  
  (END) Dow Jones Newswires
  
  April 17, 2024 12:37 ET (16:37 GMT)
- --Wedbush Cuts Price Target on Apellis Pharmaceuticals to $57 From $67, Keeps Neutral Rating, from 7:42AM ET on Wednesday Apr 17, 2024 by MT Newswires
  7:42AM ET on Wednesday Apr 17, 2024 by MT Newswires
  Companies Mentioned: APLS
  07:42 AM EDT, 04/17/2024 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contac...
Apr 15, 2024
- DJ Apellis Pharmaceuticals Price Target Maintained With a $92.00/Share by HC Wainwright & Co., from 7:17AM ET on Monday Apr 15, 2024 by Dow Jones
  7:17AM ET on Monday Apr 15, 2024 by Dow Jones
  Companies Mentioned: APLS
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/APLS/analyst-ratings
  
  (END) Dow Jones Newswires
  
  April 15, 2024 07:17 ET (11:17 GMT)
Apr 9, 2024
- Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing, from 4:33PM ET on Tuesday Apr 09, 2024 by MT Newswires
  4:33PM ET on Tuesday Apr 09, 2024 by MT Newswires
  Companies Mentioned: APLS
  04:33 PM EDT, 04/09/2024 (MT Newswires) -- Pascal Deschatelets, Chief Scientific Officer, on April 08, 2024, sold 69,107 shares in Apellis Pharmaceuticals (APLS) for $3,743,605. Following the Form 4 filing with the SEC, Deschatelets has control over...
- DJ Apellis Pharmaceuticals Price Target Maintained With a $85.00/Share by Needham, from 6:37AM ET on Tuesday Apr 09, 2024 by Dow Jones
  6:37AM ET on Tuesday Apr 09, 2024 by Dow Jones
  Companies Mentioned: APLS
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/APLS/analyst-ratings
  
  (END) Dow Jones Newswires
  
  April 09, 2024 06:37 ET (10:37 GMT)

Yesterday
- --Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating, from 21 hours ago by MT Newswires
  21 hours ago by MT Newswires
  Companies Mentioned: CRSP
- Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024, from 8:00AM ET on Thursday Apr 18, 2024 by PR Newswire
  8:00AM ET on Thursday Apr 18, 2024 by PR Newswire
  Companies Mentioned: BPMC
- Intra-Cellular Therapies Prices $500 Million Stock Offering, from 3:42AM ET on Thursday Apr 18, 2024 by MT Newswires
  3:42AM ET on Thursday Apr 18, 2024 by MT Newswires
  Companies Mentioned: ITCI
Apr 17, 2024
- Intra-Cellular Therapies Prices Public Offering of Common Stock, from 8:46PM ET on Wednesday Apr 17, 2024 by GlobeNewswire
  8:46PM ET on Wednesday Apr 17, 2024 by GlobeNewswire
  Companies Mentioned: ITCI
- Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing, from 5:51PM ET on Wednesday Apr 17, 2024 by MT Newswires
  5:51PM ET on Wednesday Apr 17, 2024 by MT Newswires
  Companies Mentioned: CRSP
- --Goldman Sachs Adjusts Price Target on Intra-Cellular Therapies to $77 From $67, Maintains Neutral Rating, from 11:40AM ET on Wednesday Apr 17, 2024 by MT Newswires
  11:40AM ET on Wednesday Apr 17, 2024 by MT Newswires
  Companies Mentioned: ITCI
- --BofA Securities Adjusts Price Target on Intra-Cellular Therapies to $91 From $82, Maintains Buy Rating, from 9:27AM ET on Wednesday Apr 17, 2024 by MT Newswires
  9:27AM ET on Wednesday Apr 17, 2024 by MT Newswires
  Companies Mentioned: ITCI
- Baird Adjusts Price Target on Intra-Cellular Therapies to $103 From $83, Maintains Outperform Rating, from 9:07AM ET on Wednesday Apr 17, 2024 by MT Newswires
  9:07AM ET on Wednesday Apr 17, 2024 by MT Newswires
  Companies Mentioned: ITCI
- TD Cowen Adjusts Price Target on Intra-Cellular Therapies to $90 From $80, Maintains Buy Rating, from 8:53AM ET on Wednesday Apr 17, 2024 by MT Newswires
  8:53AM ET on Wednesday Apr 17, 2024 by MT Newswires
  Companies Mentioned: ITCI
- --Morgan Stanley Lifts Price Target on Intra-Cellular Therapies to $92 From $85, Says Study 501 Exceeds Its Highest Expectations; Overweight Kept, from 7:17AM ET on Wednesday Apr 17, 2024 by MT Newswires
  7:17AM ET on Wednesday Apr 17, 2024 by MT Newswires
  Companies Mentioned: ITCI

Apellis Pharmaceuticals Inc
NASDAQ:APLSUnited States

Search Criteria

Apr 17, 2024

DJ Apellis Pharmaceuticals Is Maintained at Neutral by Wedbush, from 12:37PM ET on Wednesday Apr 17, 2024 by Dow Jones

--Wedbush Cuts Price Target on Apellis Pharmaceuticals to $57 From $67, Keeps Neutral Rating, from 7:42AM ET on Wednesday Apr 17, 2024 by MT Newswires

Apr 15, 2024

DJ Apellis Pharmaceuticals Price Target Maintained With a $92.00/Share by HC Wainwright & Co., from 7:17AM ET on Monday Apr 15, 2024 by Dow Jones

Apr 9, 2024

Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing, from 4:33PM ET on Tuesday Apr 09, 2024 by MT Newswires

DJ Apellis Pharmaceuticals Price Target Maintained With a $85.00/Share by Needham, from 6:37AM ET on Tuesday Apr 09, 2024 by Dow Jones

Peers Headlines

Yesterday

--Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating, from 21 hours ago by MT Newswires

Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024, from 8:00AM ET on Thursday Apr 18, 2024 by PR Newswire

Intra-Cellular Therapies Prices $500 Million Stock Offering, from 3:42AM ET on Thursday Apr 18, 2024 by MT Newswires

Apr 17, 2024

Intra-Cellular Therapies Prices Public Offering of Common Stock, from 8:46PM ET on Wednesday Apr 17, 2024 by GlobeNewswire

Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing, from 5:51PM ET on Wednesday Apr 17, 2024 by MT Newswires

--Goldman Sachs Adjusts Price Target on Intra-Cellular Therapies to $77 From $67, Maintains Neutral Rating, from 11:40AM ET on Wednesday Apr 17, 2024 by MT Newswires

--BofA Securities Adjusts Price Target on Intra-Cellular Therapies to $91 From $82, Maintains Buy Rating, from 9:27AM ET on Wednesday Apr 17, 2024 by MT Newswires

Baird Adjusts Price Target on Intra-Cellular Therapies to $103 From $83, Maintains Outperform Rating, from 9:07AM ET on Wednesday Apr 17, 2024 by MT Newswires

TD Cowen Adjusts Price Target on Intra-Cellular Therapies to $90 From $80, Maintains Buy Rating, from 8:53AM ET on Wednesday Apr 17, 2024 by MT Newswires

--Morgan Stanley Lifts Price Target on Intra-Cellular Therapies to $92 From $85, Says Study 501 Exceeds Its Highest Expectations; Overweight Kept, from 7:17AM ET on Wednesday Apr 17, 2024 by MT Newswires